Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Trial Profile

The MAX Study: A Randomised Phase II/III Study to Evaluate the Role of Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 Sep 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Mitomycin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MAX
  • Most Recent Events

    • 12 Sep 2018 Results published in the Annals of Oncology
    • 20 Jan 2018 Results (n=145) assessing the prognostic impact of single nucleotide polymorphisms variants (COL4A2, PPP1R17 and ARHGAPP44) and predictive effect on bevacizumab in patients from this trial, presented at the 2018 Gastrointestinal Cancers Symposium.
    • 03 Jun 2014 Results of the predictive/prognostic impact of SNP genotype presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top